Acute skin graft rejection can be prevented and treated in rat models by malononitrilamides.
Schorlemmer
H U
HU
Research Laboratory, Hoechst Marion Roussell (HMR), Marburg, Germany.
Schwab
W
W
Ruuth
E
E
Kurrle
R
R
D000208:Acute Disease; D000480:Alkynes; D000818:Animals; D016572:Cyclosporine / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects* / Q000276:immunology; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007555:Isoxazoles; D009570:Nitriles / Q000627:therapeutic use*; D051381:Rats; D011916:Rats, Inbred F344; D011917:Rats, Inbred Lew; D011919:Rats, Inbred Strains; D016038:Skin Transplantation / Q000276:immunology*; D013997:Time Factors
D000480:Alkynes; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D009570:Nitriles; C102911:X 910279; C115284:2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide; D016572:Cyclosporine